The global blood screening market is expanding steadily, driven by increasing blood donations, rising awareness of transfusion-transmitted infections, and stringent regulations governing blood safety. Blood screening plays a critical role in identifying infectious agents and reducing the risk of disease transmission through transfusions. Growing demand for safe blood products, improvements in diagnostic technologies, and investments in healthcare infrastructure are encouraging hospitals, blood banks, and diagnostic laboratories to adopt advanced screening solutions. 

The global blood screening market size was valued at USD 3.4 billion in 2024 and is projected to grow from USD 4.2 billion in 2026 to USD 6.6 billion by 2030, registering a CAGR of 11.9% from 2025 to 2030. North America dominated the market, accounting for 38.4% of global revenue in 2024, while Asia Pacific is expected to be the fastest-growing region, with a projected CAGR of 13.7% over the forecast period. 

Download a free sample copy of the Blood Screening Market report to understand detailed coverage and inclusions in the final report 

Core Market Segmentation

The global blood screening market is segmented by product, technology, and region. Reagents, molecular testing platforms, and advanced laboratory instruments are central to the industry's development.

By Product

The reagents segment accounted for 73.4% of market revenue in 2024, making it the leading product category. Reagents are essential consumables used in screening procedures and must be replenished regularly as laboratories process blood samples. 

• Reagents: Include the chemical and biological materials required to detect infectious agents and generate reliable screening results. Recurring demand from blood banks and laboratories supports this segment's leading position.

• Instruments: Include analyzers and testing equipment used to conduct screening procedures. The segment is projected to grow at a CAGR of 10.8% over the forecast period, supported by demand for automated systems, improved laboratory productivity, and higher testing accuracy. 

As laboratories seek to increase testing capacity and reduce manual processing, instrument manufacturers are focusing on automation, efficient workflows, and dependable analytical performance.

By Technology

The nucleic acid amplification test (NAT) segment held 41.2% of market revenue in 2024, establishing itself as the leading technology category. NAT detects genetic material from infectious agents and can identify certain infections earlier than conventional antibody-based methods. This capability is particularly valuable for reducing the risk of transfusion-transmitted infections. 

• Nucleic Acid Amplification Test (NAT): Supports sensitive detection of pathogens and is widely used where early identification of infection is important.

• ELISA: Enzyme-linked immunosorbent assays detect specific antigens or antibodies and remain an established screening option.

• Chemiluminescence Immunoassay (CLIA): Offers automated detection capabilities and supports high-throughput laboratory testing.

• Next-Generation Sequencing (NGS): Enables extensive genetic analysis and is expected to grow at a CAGR of 16.5% over the forecast period, reflecting increasing interest in advanced molecular testing. 

• Western Blotting: Provides targeted protein analysis and has applications in specialized diagnostic testing.

The continued development of molecular diagnostic methods is expected to improve detection capabilities and expand the range of screening applications. However, the selection of technology depends on cost, testing volume, infrastructure, regulatory requirements, and the sensitivity needed for specific applications.

By Region

North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa represent the major regional markets.

• North America: Dominated the global market with a 38.4% revenue share in 2024, supported by advanced healthcare infrastructure, established blood donation systems, and stringent safety requirements.

• Europe: Benefits from established diagnostic laboratories, blood safety standards, and investments in modern screening technologies.

• Asia Pacific: Is projected to grow at a 13.7% CAGR, driven by expanding healthcare infrastructure, increasing awareness of blood safety, and growing demand for diagnostic services.

• Latin America: Offers opportunities as healthcare providers strengthen blood collection systems and improve access to diagnostic testing.

• Middle East and Africa: May benefit from investments in laboratory infrastructure, blood donation programs, and healthcare modernization. 

Key Market Trends & Drivers

Increasing Blood Donations and Transfusion Safety Requirements

The growing number of blood donations is a major driver of screening demand. Each donation must undergo appropriate testing to help protect recipients from transfusion-transmitted infections. As donation programs expand, blood banks require consistent supplies of reagents and reliable testing equipment.

Regulatory requirements also encourage healthcare providers to maintain comprehensive screening procedures. These requirements support continued investment in validated diagnostic methods and quality assurance systems.

Technological Advancements and Automation

Automation is becoming increasingly important as laboratories manage larger sample volumes and seek to reduce processing times. Automated screening platforms can streamline sample handling, standardize procedures, and improve operational efficiency.

Advances in molecular diagnostics are also helping laboratories detect infectious agents with greater sensitivity. Improvements in instrument design and testing workflows are expected to support further technology adoption.

Growing Demand for Molecular Screening

NAT technology is particularly important because it can identify pathogen genetic material during early stages of infection. Its established role in blood safety supports continued demand for molecular screening systems.

Meanwhile, developments in sequencing technologies are creating opportunities for more comprehensive genetic analysis. As these technologies advance, laboratories may gain access to additional testing capabilities, although costs and implementation complexity remain important considerations.

Expansion of Healthcare Infrastructure

Investment in healthcare facilities across developing economies is increasing the need for modern diagnostic laboratories and dependable blood screening services. Improved laboratory capacity and greater awareness of transfusion safety can support the adoption of advanced testing solutions.

Partnerships among diagnostic companies, healthcare institutions, and public health organizations can further strengthen screening infrastructure and improve access to reliable testing.

Market Restraints

High initial equipment costs and ongoing consumable expenses can limit adoption, particularly among smaller laboratories. Advanced molecular screening systems also require trained personnel, maintenance, and appropriate quality control procedures.

Differences in healthcare infrastructure and purchasing capacity across countries may create uneven adoption rates. Manufacturers must therefore balance technological performance with affordability and ease of use.

Looking for more specific insights? Customize this report to suite your business needs

Major Competitors and Industry Landscape

The global blood screening market features established diagnostic companies that compete through product innovation, laboratory automation, testing accuracy, and expanded diagnostic portfolios. Companies are investing in advanced screening technologies and strengthening partnerships with healthcare providers to meet evolving blood safety requirements.

Key companies operating in the market include:

• F. Hoffmann-La Roche Ltd.

• Grifols, S.A.

• Abbott Laboratories

• Bio-Rad Laboratories, Inc.

• Danaher Corporation

• Thermo Fisher Scientific, Inc.

• Becton, Dickinson and Company (BD)

• Siemens Healthineers

• Ortho-Clinical Diagnostics

• bioMérieux

These companies participate in different areas of diagnostic testing, including reagents, molecular assays, immunoassays, and automated laboratory instruments. Competition is increasingly focused on improving screening sensitivity, increasing sample-processing capacity, and developing solutions that help laboratories operate efficiently.

Product innovation, strategic collaborations, and geographic expansion are expected to remain important competitive strategies as demand for reliable blood screening solutions increases.

About us:

Grand View Research, a market research and consulting company, provides syndicated research reports, customized research reports, and consulting services. Grand View Research database is used by the world's renowned academic institutions and Fortune 500 companies to understand the global and regional business environment. Our database features thousands of statistics and in-depth analysis on 46 industries in 25 major countries worldwide.

Explore U.S. Healthcare Facility Mapping & Intelligence Platform - https://www.grandviewresearch.com/horizon/hospital-database